Multimodal predictors for precision immunotherapy

Area of Science:

• Cancer Immunotherapy
• Tumor Microenvironment (TME) Research
• Precision Oncology

Background:

• Immune checkpoint blockade (ICB) shows promise in cancer treatment but benefits only a subset of patients.
• The tumor microenvironment (TME) presents multifaceted suppressive pathways limiting ICB efficacy.
• Current single-parameter biomarkers for ICB response are imperfect and difficult to clinically implement.

Purpose of the Study:

• To review strategies for developing precision immuno-oncology (IO) approaches.
• To identify methods for understanding individual patient immune responses to cancer immunotherapy.
• To explore the translation of complex immune profiling into clinically applicable predictors for optimal IO treatment selection.

Main Methods:

• Discussion of holistic approaches to profile human tumor microenvironments.
• Identification of measurable parameters that capture the complexity of a patient's immune status.
• Review of strategies to translate research findings into clinical practice for precision IO.

Main Results:

• Holistic profiling of the TME and treatment responses can reveal critical rate-limiting factors of antitumor immunity.
• Development of multimodal predictors is essential for selecting the best IO treatment for individual patients.
• Understanding the interplay of multiple cell types in antitumor immune response is crucial for therapeutic restoration.

Conclusions:

• Precision IO requires a comprehensive understanding of individual patient immune profiles to overcome treatment resistance.
• Multimodal predictors derived from holistic TME analysis are necessary for effective patient stratification.
• Integrating precision IO research into clinical settings will enhance the efficacy of cancer immunotherapy.